TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14581122

Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topically applied capsaicin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Systemic treatment with gabapentin
Number of subjects: 40
Study: 10809260

Group type: COMPARATOR
Intervention: Dopamine (4-hr infusions at doses of placebo, 3, 7, and 12 microg/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dobutamine (4-hr infusions at doses of placebo, 3, 7, and 12 microg/kg/min)
Number of subjects: 12
Study: 8613041

Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg.kg‐1.h‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Duodenal lipid (20% Intralipid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Duodenal saline (0.9% saline)
Number of subjects: 12
Study: 9071422

Group type: EXPERIMENTAL
Intervention: Azithromycin 2.0 g orally
Number of subjects: 724

Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg intramuscularly
Number of subjects: 724
Study: 3340314

Group type: EXPERIMENTAL
Intervention: Ionic contrast media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-ionic contrast media
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29730251

Group type: EXPERIMENTAL
Intervention: left prefrontal iTBS
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: combined right prefrontal cTBS and left prefrontal iTBS
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: right prefrontal cTBS
Number of subjects: 56

Group type: COMPARATOR
Intervention: sham‐TBS
Number of subjects: 56
Study: 28034709

Group type: EXPERIMENTAL
Intervention: Dual wire-maintaining technique (DWMT)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Conventional technique (CT)
Number of subjects: 241
Study: 25600977

Group type: EXPERIMENTAL
Intervention: Low C-form (10 mg lenvatinib, <4% crystalline)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High C-form (10 mg lenvatinib, 38% crystalline)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Reference C-form (10 mg lenvatinib, 15% crystalline)
Number of subjects: 59
Study: 23349433

Group type: EXPERIMENTAL
Intervention: Shortened subseries with W = 7 tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Entire sequence of visual fields
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Window lengths 6 ≤ W ≤ 9
Number of subjects: 0
Study: 20842170

Group type: EXPERIMENTAL
Intervention: Long-chain pullulan (indigestible)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Medium-chain pullulan (slowly but completely digestible)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Maltodextrin (rapidly digestible)
Number of subjects: 35
Study: 17433718

Group type: EXPERIMENTAL
Intervention: Participants with autism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without autism)
Number of subjects: 0
Study: 16418630

Group type: EXPERIMENTAL
Intervention: Left‐sided blindness by enucleation (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Right‐sided blindness (group 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No visual impairment (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 14507756

Group type: EXPERIMENTAL
Intervention: 2% econazole
Number of subjects: 116

Group type: COMPARATOR
Intervention: 5% natamycin
Number of subjects: 116
Study: 10874974

Group type: EXPERIMENTAL
Intervention: Intraarterial chemoperfusion (CP) with mitoxantrone (820 mg/m2 for 1-2 hours)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intraarterial embolization therapy (ET) using Histoacryl or Ethibloc
Number of subjects: 30
Study: 7594333

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole by slow intravenous injection twice daily for 3 days (six injections)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole by slow intravenous injection twice daily for 3 days (six injections)
Number of subjects: 82
Study: 2102066

Group type: EXPERIMENTAL
Intervention: kanamycin sulphate alternated to polydeoxyribonucleotide vaginal suppositories
Number of subjects: 240

Group type: COMPARATOR
Intervention: kanamycin sulphate alternated to placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: PDRN at different dosages
Number of subjects: 240
Study: 396654

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ) 75 mg/day for 10 days followed by 50 mg/day for 20 days
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (CB) 300 mg/day followed by 200 mg/day
Number of subjects: 112
Study: 30661552

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Common rapid response classifications (≥ 10% reduction in binge eating at week 1, ≥ 70% reduction in binge eating at week 4)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Latent change trajectories
Number of subjects: 86
Study: 28600039

Group type: EXPERIMENTAL
Intervention: 800 mg of misoprostol vaginally every 12 hours after an 800-μg vaginal loading dose
Number of subjects: 173

Group type: COMPARATOR
Intervention: 400 mg of misoprostol sublingually every 12 hours after an 800-μg vaginal loading dose
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Sequential sublingual misoprostol after a vaginal loading dose
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Sequential sublingual misoprostol regimen
Number of subjects: 173
Study: 26296562

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (specialist mental health professional and educational package)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low-intensity intervention (postal campaign and biannual guidelines)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Practice-as-usual (PAU)
Number of subjects: 54
Study: 23819237

Group type: EXPERIMENTAL
Intervention: Heat-sensitized acupoints detection using moxibustion sensitization method
Number of subjects: 60
Study: 21835317

Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19473601

Group type: EXPERIMENTAL
Intervention: HX575 (100 IU/kg body weight, subcutaneous, three-times-weekly for 4 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epoetin beta (100 IU/kg body weight, subcutaneous, three-times-weekly for 4 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HX575 and Epoetin beta
Number of subjects: 80
Study: 17978603

Group type: EXPERIMENTAL
Intervention: Blockade of the renin‐angiotensin system in patients with type 2 diabetes with or without chronic kidney disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renin‐angiotensin system‐blocking agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of other agents if needed to meet blood pressure goal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 0
Study: 14575725

Group type: EXPERIMENTAL
Intervention: Serum melatonin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Urinary 6-sulfatoxymelatonin (aMT6s)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Melatonin peak
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nocturnal melatonin peak secretion timing
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Urinary aMT6s concentrations
Number of subjects: 14
Study: 11124759

Group type: EXPERIMENTAL
Intervention: Modified Sham Feeding (MSF) with 38 g fat
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control: Water
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control: Lunch with 38 g fat
Number of subjects: 10
Study: 9625833

Group type: EXPERIMENTAL
Intervention: Adenosquamous carcinoma
Number of subjects: 10

Group type: COMPARATOR
Intervention: Adenocarcinoma
Number of subjects: 10

Group type: COMPARATOR
Intervention: Squamous cell carcinoma
Number of subjects: 10
Study: 7653819

Group type: EXPERIMENTAL
Intervention: Meperidine 0.25%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5%
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.9% Sodium Chloride (saline)
Number of subjects: 45
Study: 2691568

Group type: EXPERIMENTAL
Intervention: Intramuscular recombinant interferon alpha‐2a (r‐IFN) at doses of 4.5 megaunits thrice weekly for 4 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Overall control
Number of subjects: 33
Study: 4558895

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 69
Study: 31204839

Group type: EXPERIMENTAL
Intervention: AccessEI, a 6-10 week online therapist-assisted parenting program
Number of subjects: 206

Group type: COMPARATOR
Intervention: Face-to-face (FTF) treatment, 1-week treatment
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: AccessEI
Number of subjects: 206

Group type: COMPARATOR
Intervention: FTF treatment
Number of subjects: 206
Study: 28338721

Group type: EXPERIMENTAL
Intervention: Cumulus (conventional threshold)
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Altocumulus (higher threshold)
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Cirrocumulus (higher threshold)
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Mean of standardized adjusted Altocumulus and Cirrocumulus dense area measures
Number of subjects: 1298
Study: 26582852

Group type: EXPERIMENTAL
Intervention: Echogenic needle and echogenic non-stimulating catheter
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-echogenic needle and stimulating catheter
Number of subjects: 78
Study: 23726159

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target of less than 130 mm Hg
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Systolic blood pressure target of 130-149 mm Hg
Number of subjects: 3020
Study: 20721696

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Suction drain (Group 1)
Number of subjects: 50
Study: 19011946

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No preoperative chemoradiation therapy (non-CRT)
Number of subjects: 125
Study: 16205837

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg for 22 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15458015

Group type: EXPERIMENTAL
Intervention: Ammonia exposure (25 ppm)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ammonia exposure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 12
Study: 10841126

Group type: EXPERIMENTAL
Intervention: Cardiotocography plus fetal ECG
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Cardiotocography
Number of subjects: 1038
Study: 9084062

Group type: EXPERIMENTAL
Intervention: CI-988 (50 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CI-988 (100 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15374345

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 56
Study: 2410320

Group type: EXPERIMENTAL
Intervention: Dioctyl sodium sulfosuccinate (DSS) 100 mg three times daily for 4 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dioctyl sodium sulfosuccinate (DSS) 100 mg three times daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28973638

Group type: EXPERIMENTAL
Intervention: Interspinous process device (IPD)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standalone decompressive surgery (SDS)
Number of subjects: 163
Study: 26890230

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT) combined with Neuromuscular Electrical Stimulation (NMES) and conventional physical therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional physical therapy alone
Number of subjects: 27
Study: 24671049

Group type: EXPERIMENTAL
Intervention: Self-Help Intervention Program
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 369
Study: 22069972

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) 3.5 mL intra-knee-articular injections
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sodium hyaluronate (SH) 2 mL intra-knee-articular injections
Number of subjects: 30
Study: 19320670

Group type: EXPERIMENTAL
Intervention: Internet-based interventions (IBI) for problem drinking; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Check Your Drinking screener (IBI for problem drinkers); specific dosage and duration not mentioned.
Number of subjects: 0
Study: 17874834

Group type: EXPERIMENTAL
Intervention: Mushroom (Agaricus bisporus) extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-vitro analysis with mushroom extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparative gas chromatography analysis
Number of subjects: 0
Study: 15547570

Group type: EXPERIMENTAL
Intervention: 3 sessions of physical practice on suturing a pig's foot
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 2 sessions of physical practice and 1 session of mental imagery rehearsal
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 1 session of physical practice and 2 sessions of imagery rehearsal
Number of subjects: 65
Study: 11907839

Group type: EXPERIMENTAL
Intervention: Methotrexate 0.25% gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9036910

Group type: EXPERIMENTAL
Intervention: Intra-articular triamcinolone acetonide (3 injections at day 1, 8, and 22 over 4 weeks)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intra-articular triamcinolone acetonide
Number of subjects: 7
Study: 7960300

Group type: EXPERIMENTAL
Intervention: Individual interview in the workplace
Number of subjects: 621

Group type: COMPARATOR
Intervention: Group-administered questionnaire in the workplace
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Individual interview off the worksite
Number of subjects: 621

Group type: COMPARATOR
Intervention: Urinalysis
Number of subjects: 621
Study: 2962807

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Injection therapy
Number of subjects: 12
Study: 112944

Group type: EXPERIMENTAL
Intervention: Intravenous protirelin (0.5 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Niacin (2 mg)
Number of subjects: 17
Study: 30937431

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 4099

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening beyond 5 years
Number of subjects: 4099

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 4099
Study: 28464238

Group type: EXPERIMENTAL
Intervention: Prophylactic ondansetron
Number of subjects: 3
Study: 25881496

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 1759
Study: 24011955

Group type: EXPERIMENTAL
Intervention: Fixed-dose linezolid
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Weight-based dosing of vancomycin
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: Fixed-dose linezolid and weight-based dosing of vancomycin
Number of subjects: 1079
Study: 22358277

Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming (RAP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard CPB (crystalloid priming)
Number of subjects: 62
Study: 19192880

Group type: COMPARATOR
Intervention: Former group (TKA from October 2000 to January 2005)
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Latter group (TKA from January 2005 to October 2007)
Number of subjects: 707
Study: 17678670

Group type: EXPERIMENTAL
Intervention: Strength training (n=7), twice a week for 6 weeks, including dumbbell bicep curls, wrist flexions, and wrist extensions
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (n=4), maintained normal activities
Number of subjects: 11
Study: 15008017

Group type: EXPERIMENTAL
Intervention: Inching technique
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 46
Study: 12733373

Group type: EXPERIMENTAL
Intervention: Domestic intravenous Turbutalin Sulfate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bricanyl (control)
Number of subjects: 120
Study: 9677793

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg as a priming dose and 90 mg infused over 24 hours)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg + 300 mg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg + 0.9 mg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combination of ketorolac and buprenorphine (30 mg of K as priming dose and 60 + 0.6 mg in infusion)
Number of subjects: 300

Group type: COMPARATOR
Intervention: All therapeutic schemes
Number of subjects: 300
Study: 7837949

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg orally every 8 h for 36 h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (resting values of RBF, GFR, or renal vascular resistance)
Number of subjects: 8
Study: 3421264

Group type: EXPERIMENTAL
Intervention: Labetalol pretreatment (20 mg IV followed by 10 mg increments up to 1 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no antihypertensive therapy)
Number of subjects: 25
Study: 31914034

Group type: EXPERIMENTAL
Intervention: So-Cheong-Ryong-Tang (SCRT) administered 3 times a day for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo administered 3 times a day for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: So-Cheong-Ryong-Tang (SCRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30985612

Group type: EXPERIMENTAL
Intervention: Drain use
Number of subjects: 105116

Group type: COMPARATOR
Intervention: No drain use
Number of subjects: 105116
Study: 28115818

Group type: EXPERIMENTAL
Intervention: Health for Hearts United intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 0
Study: 25344370

Group type: EXPERIMENTAL
Intervention: Low-T2 group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Higher-T2 group
Number of subjects: 100
Study: 22900583

Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg) with Ritonavir (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ritonavir (100 mg)
Number of subjects: 10
Study: 21626525

Group type: EXPERIMENTAL
Intervention: Standard therapy (24, 48, or 72 weeks)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Variable therapy (24, 48, or 72 weeks)
Number of subjects: 454

Group type: COMPARATOR
Intervention: IL28B type (CC, CT, TT)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: RVR patients
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Non-RVR patients
Number of subjects: 454
Study: 19086709

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 to 100 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17239870

Group type: EXPERIMENTAL
Intervention: Phenazopyridine (200 mg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 15492552

Group type: EXPERIMENTAL
Intervention: Pylorus-preserving pancreaticoduodenectomy (PPPD)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard Whipple (SW) procedure
Number of subjects: 170
Study: 11341082

Group type: EXPERIMENTAL
Intervention: Contrast-guided extrathoracic subclavian vein approach
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cephalic approach
Number of subjects: 200
Study: 9484873

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 200 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 600 mg
Number of subjects: 76
Study: 7699611

Group type: EXPERIMENTAL
Intervention: McNeil‐Sjöström Scale for obstetric complications
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Lewis et al. scale
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Parnas et al. scale
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: McNeil‐Sjöström Scale
Number of subjects: 140
Study: 3476244

Group type: EXPERIMENTAL
Intervention: Registration method (GR) - dentists asked to complete a separate form for every adult patient treated in one day.
Number of subjects: 479

Group type: COMPARATOR
Intervention: Estimation method (GE) - dentists asked to make general estimates of time spent on caries prevention.
Number of subjects: 479
Study: 29503217

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy-based pain management program
Number of subjects: 60
Study: 27561981

Group type: EXPERIMENTAL
Intervention: Immediate postpartum insertion of the etonogestrel-releasing contraceptive implant
Number of subjects: 96

Group type: COMPARATOR
Intervention: 6-week postpartum insertion of the etonogestrel-releasing contraceptive implant
Number of subjects: 96
Study: 25799024

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral Internet-based intervention, 2 weekly 45-minute sessions over 5 weeks (10 sessions total)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 159
Study: 23063703

Group type: EXPERIMENTAL
Intervention: Tenodesis of the long head of the biceps (LHB) performed in 19 patients (group 2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Hemiarthroplasty without tenodesis of the long head of the biceps (LHB) in 18 patients (group 1)
Number of subjects: 37
Study: 20044497

Group type: EXPERIMENTAL
Intervention: Press-fit fixation with a porous bone cylinder (P)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Interference screw (I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Press-fit fixation (P)
Number of subjects: 20
Study: 18198064

Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV) procedure
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: ECV procedure
Number of subjects: 178